Meeting Minutes, Open Session, Drug Utilization Review Board October 20, 2021 10am to 2pm		
Drug Utilization Review Board *Due to COVID-19, this meeting was held virtually.	**DUR Board Members:** Moneeshindra Mittal, MD, Chair (Present) James Backes, PharmD, Interim Chair (Present) Jennifer Clair, MD (Present) Gregory Burger, PharmD, CPPS, FASHP, EMT (Present) Michele Reisinger, DNP, APRN, FNP-BC (Present) Kristen Powell, PharmD (Present) Arthur Snow, MD (Present) **KDHE/DHCF/Contractor Staff:** Annette Grant, RPh. (Present) Victor Nguyen, PharmD (Present) Carol Arace, Administrative Specialist (Present) **DXC Technology Staff/KEPRO Staff** Karen Kluczykowski, RPh (Present) Kathy Kaesewurm, RN, BSN (Present) Harry Vu, PharmD (Present) Christina Faulkner, PharmD, BCPS (Present) **MCO Staff:** Sunny Bounyalath, PharmD, UnitedHealthcare Community Plan (Absent) Mark DeMary, PharmD, Aetna Better Health of Kansas (Absent) Angie Yoo, PharmD, Sunflower State Health Plan (Present) Kelly Flannigan, PharmD, UnitedHealthcare Community Plan (Present)	**Public Attendees**: Ann Nelson, Ash Dave, Chanda Gross, David Cram, Doug Wood, Emma Selm-Keck, Eric Berthelot, Erin Hohman, Gina Heinen, Jenny Carrell, Jim Baumann, Joseph Lance Salazar, Karen Floeder, Keith Gulley, Kurt Hendrickson, Melissa Basil, Donna Osterlund, Phil King, Rob Kilo, Sarah Blankenship, Tami Sova, Raquel Jordan, Ricki Roberson. (Only individuals that provided their full name are listed)

TOPIC	DISCUSSION	DECISION
I. Call to Order	Dr. Mittal called the meeting to order at 10:05 AM.	
Announcements and Introductions	No announcements or introductions.	
II. Old Business **A. Review and Approval of July 21, 2021 Meeting Minutes**	**Board Discussion:** Dr. Mittal asked if there were any amendments/changes to the minutes requested.	Dr. Snow motioned to approve. Dr. Backes seconded the motion. The motion was approved unanimously.
III. New Business **A. Revised Prior Authorization (PA) Criteria** **1. Ankylosing Spondylitis Agents**	**Background:** This revision included the addition of Taltz® to the list of agents requiring prior authorization. **Public Comment:** Erin Hohman, Abbvie, yielded her time back to the Board. Ash Dave, Amgen, yielded his time back to the Board. **Board Discussion:** None.	Dr. Burger motioned to approve. Dr. Snow seconded the motion. The motion was approved unanimously.
2. Crohn's Disease Agents	**Background:** This Revision included the addition of Avsola™, clarifications regarding dosing limitations, and allowance for alternative dosing based on therapeutic drug monitoring. Dr. Nguyen also touched on questions on Crohn's Criteria from the July 2021 meeting. **Public Comment:** Erin Hohman, Abbvie, yielded her time back to the board. Ash Dave, Amgen, yielded his time back to the board. **Board Discussion:** None.	Dr. Reisinger motioned to approve. Dr. Powell seconded the motion. The motion was approved unanimously.

TOPIC	DISCUSSION	DECISION
3. Ulcerative Colitis Agents	**Background:** This revision included review of all agents, including indications and dosing. In addition, a warning for JAK inhibitors was noted. Also included was an addition to the criteria allowing for dose modifications based on therapeutic drug monitoring. **Public Comment:** Erin Hohman, Abbvie, yielded her time back to the Board. Ash Dave, Amgen, yielded his time back to the Board. James Bauman, Pfizer, yielded his time back to the Board. **Board Discussion:** None.	Dr. Powell motioned for approval as amended. Dr. Backes seconded the motion. The motion was approved unanimously.
4. Migraine Prophylaxis Agents	**Background:** This revision included the addition of Qulipta® and corrects dosing frequency for Vyepti®. **Public Comment:** Erin Hohman, Abbvie, yielded her time back to the Board. Ash Dave, Amgen, yielded his time back to the Board. **Board Discussion:** None.	Dr. Burger motioned for approval as amended. Dr. Snow seconded the motion. The motion was approved unanimously.
5. Synagis®	**Background:** This revision added language to allow for expanded coverage based on the Centers for Disease Control and Prevention (CDC) reports on respiratory syncytial virus (RSV) activity in the state. Ms. Grant added that changes to criteria in between meetings rarely occur, and if it does, it is to increase access, which is allowed. The State action would then be presented at the next meeting. Provider feedback and current research on this need was taken into consideration. KDHE Secretary Dr. Norman approved the State action and timing, as being necessary.	Dr. Powell motioned for approval as amended. Dr. Snow seconded the motion. The motion was approved unanimously.

TOPIC	DISCUSSION	DECISION
	Public Comment: None. **Board Discussion:** None.	
6. Multiple Sclerosis	**Background:** This revision included the addition of Ponvory™ and clarification regarding the applicability of the PDL PA statement due to Zeposia's lateral approval for ulcerative colitis (UC). **Public Comment:** None. **Board Discussion:** None.	Dr. Backes motioned for approval as amended. Dr. Powell seconded the motion. The motion was approved unanimously.
7. Non-Preferred PDL PA Criteria	**Background:** The Non-Preferred PDL PA criteria were last updated in July 2019. This revision included the addition of a list of PDL drug classes no longer requiring annual PDL PA renewal. **Public Comment:** None. **Board Discussion:** None.	Dr. Burger motioned to approve. Dr. Snow seconded the motion. The motion was approved unanimously.
8. Oncology Agents	**Background:** This revision included the addition of several drugs to the list of agents requiring prior authorization. **Public Comment:** None. **Board Discussion:** None.	Dr. Powell motioned to approve. Dr. Burger seconded the motion. The motion was approved unanimously.

TOPIC	DISCUSSION	DECISION
9. Oncology- Auxiliary Treatment Agents	**Background:** This revision included the addition of several drugs to the list of agents requiring prior authorization. **Public Comment:** None. **Board Discussion:** None.	Dr. Backes motioned to approve. Dr. Clair seconded the motion. The motion was approved unanimously.
10. Enzyme Replacement Therapy	**Background:** This revision included the migration of Elaprase® and adjustments to the criteria. Dr. Nguyen also brought to the Board's attention that this PA will no longer need annual PA renewal. **Public Comment:** None. **Board Discussion:** None.	Dr. Snow motioned to approve. Dr. Backes seconded the motion. The motion was approved unanimously. Board voted to uphold decision with verbal "Aye."
11. Minimum Requirements Prior Authorization	**Background:** This revision included the migration of Hetlioz®, Hetlioz LQ™, Nplate® and Promacta® to the list of agents requiring prior authorization. **Public Comment:** None. **Board Discussion:** None	Dr. Powell motioned to approve. Dr. Burger seconded the motion. The motion was approved unanimously.
B. New Prior Authorization (PA) Criteria **1. Aduhelm ™ (aducanumab-avwa) injection**	**Background:** Aduhelm™ is a monoclonal antibody for the treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia. The prior authorization criteria were proposed to ensure appropriate use based upon the FDA-approved labeling information and clinical guidelines.	Dr. Powell motioned to approve. Dr. Reisenger seconded the motion.

TOPIC	DISCUSSION	DECISION
	Public Comment: Tami Sova, Biogen, expressed concern over the duration of initial prior authorization and provided information on upcoming trials/data. **Board Discussion:** Dr. Powell expressed agreeance with the State on criteria and asked about when to expect new data on Aduhelm™.	The motion was approved unanimously.
C. Miscellaneous Items **1. Blanket Statements**	**Background:** At the July and October meetings in 2019, the DUR Board approved blanket changes to existing criteria with regards PDL criteria, new/other indications, and billing code type. A summary of changes to specific criteria was be presented. The State confirmed with the Board all the PA documents that were updated with these blanket statements. **Public Comment:** None. **Board Discussion:** None.	Dr. Clair motioned to approve. Dr. Snow seconded the motion. The motion was approved unanimously.
2. Fee- for- Service Annual Program Assessment	**Background:** The annual program assessment for the Medicaid fee-for-service population was presented by Dr. Faulkner to show drug trends over the past state fiscal year. Ms. Grant provided some explanation to items on the presentation for members of the Board who might not be familiar with the information. **Public Comment:** None. **Board Discussion:** None.	None.

TOPIC	DISCUSSION	DECISION
3. Managed Care Annual Program Assessment	**Background:** Aetna Better Health of Kansas, Sunflower State Health Plan, and UnitedHealthcare Community Plan presented reports detailing utilization trends and provider education efforts for 2020. i. Aetna Individual Report – Mark DeMary, PharmD (pre-recorded) ii. Sunflower Individual Report – Angie Yoo, PharmD iii. UnitedHealthcare Individual Report – Kelly Flannigan, PharmD **Public Comment:** None. **Board Discussion:** None.	None.
V. Adjourn	The meeting adjourned at 12:40 PM	Dr. Backes motioned to adjourn. Dr. Snow seconded the motion. Motion to adjourn carried.

The next DUR Board meeting is scheduled for January 19, 2022

All approved PA criteria are posted to the KDHE website- http://www.kdheks.gov/hcf/pharmacy/pa criteria.htm